ImpelNeuropharma_RGB.jpg
Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine
September 28, 2021 08:30 ET | Impel NeuroPharma
Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space ...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering
September 09, 2021 20:00 ET | Impel NeuroPharma
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma Announces Launch of Proposed Public Offering
September 07, 2021 16:01 ET | Impel NeuroPharma
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
September 03, 2021 08:50 ET | Impel NeuroPharma
TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal SpaceTRUDHESA Is Well Tolerated and Delivers Rapid,...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 16, 2021 08:05 ET | Impel NeuroPharma
TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
August 09, 2021 16:01 ET | Impel NeuroPharma
SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache
August 09, 2021 08:00 ET | Impel NeuroPharma
Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes Data Indicated More Than One Third of Patients Experienced Pain Freedom...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021
July 29, 2021 08:00 ET | Impel NeuroPharma
SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank
July 07, 2021 08:05 ET | Impel NeuroPharma
SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for...
ImpelNeuropharma_RGB.jpg
Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
June 16, 2021 08:00 ET | Impel NeuroPharma
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living...